Loading
Life sciences · Journal article
Molecular Cancer · October 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Despite advances in targeted therapy, effective treatment of KRAS-mutant colorectal cancer (CRC) remains challenging. Although circular RNAs (circRNAs) have emerged as important regulators of tumorigenesis, the functional significance of circRNA-encoded micropeptides in KRAS-mutant CRC remains poorly understood. Integrative transcriptomic profiling was used to identify dysregulated circRNAs in KRAS-mutant CRC. The coding potential of circRAB6A was evaluated using bioinformatic prediction, internal ribosome entry site (IRES) reporter assays, and mass spectrometry. The functional effects of circRAB6A and its encoded micropeptide were assessed using in vitro assays and orthotopic and patient-derived xenograft (PDX) models. Mechanistic studies combined RNA sequencing, co-immunoprecipitation, bio-layer interferometry, and molecular dynamics simulations. We identify circRAB6A as a highly expressed circRNA in KRAS-mutant CRC, with elevated circRAB6A abundance associated with poor clinical outcomes. circRAB6A harbors a short open reading frame and encodes a previously uncharacterized micropeptide, designated KAPEP. KAPEP promotes CRC cell proliferation, migration, and invasion in vitro and accelerates tumor growth in vivo. Mechanistically, KAPEP directly binds PTPN6 and inhibits its phosphatase activity, thereby relieving PTPN6-mediated restraint on JAK-STAT signaling and sustaining pathway activation. Our findings identify KAPEP as a functional circRNA-encoded micropeptide that promotes KRAS-mutant CRC progression through the PTPN6/JAK-STAT axis. These results highlight the KAPEP/PTPN6 interaction as a potential therapeutic vulnerability in KRAS-mutant CRC.